, ▁but ▁did ▁not ▁withdraw ▁it . ▁( In ▁ 2 0 1 3 , ▁the ▁F DA ▁rejected ▁that ▁the ▁drug ▁had ▁caused ▁excess ▁heart ▁attacks .) ▁A ▁Senate ▁Fin ance ▁Committee ▁inqu iry ▁concluded ▁in ▁ 2 0 1 0 , ▁that ▁G SK ▁had ▁sought ▁to ▁int im id ate ▁scient ists ▁who ▁had ▁concerns ▁about ▁ros ig lit az one . ▁In ▁February ▁that ▁year ▁the ▁company ▁tried ▁to ▁halt ▁publication ▁of ▁an ▁editor ial ▁about ▁the ▁controvers y ▁by ▁N issen ▁in ▁the ▁European ▁Heart ▁Journal . ▁ ▁The ▁results ▁of ▁G SK ' s ▁RE C ORD ▁trial ▁were ▁published ▁in ▁June ▁ 2 0 0 9 . ▁It ▁confirmed ▁an ▁association ▁between ▁ros ig lit az one ▁and ▁an ▁increased ▁risk ▁of ▁heart ▁failure ▁and ▁f ract ures , ▁but ▁not ▁of ▁heart ▁attack , ▁and ▁concluded ▁that ▁it ▁" does ▁not ▁increase ▁the ▁risk ▁of ▁overall ▁card i ov asc ular ▁mor bid ity ▁or ▁mort ality ▁compared ▁with ▁standard ▁gl uc ose - low ering ▁dru gs ." ▁Steven ▁N iss an ▁and ▁Kath y ▁Wol k ski ▁argued ▁that ▁the ▁study ' s ▁low ▁event ▁rates ▁reduced ▁its ▁statistical ▁power . ▁In ▁September ▁ 2 0 0 9 , ▁ros ig lit az one ▁was ▁susp ended ▁in ▁Europe . ▁The ▁results ▁of ▁the ▁RE C ORD ▁study ▁were ▁confirmed ▁in ▁ 2 0 1 3 , ▁by ▁the ▁Duke ▁C lin ical ▁Research ▁Institute , ▁in ▁an ▁independent ▁review ▁required ▁by ▁the